Silver Book Fact

Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.

Chestnut C, Skag A, Christiansen C, Recker R, et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res. 2004; 19(8): 1241-9. http://www.ncbi.nlm.nih.gov/pubmed/15231010

Reference

Title
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Publication
J Bone Miner Res
Publication Date
2004
Authors
Chestnut C, Skag A, Christiansen C, Recker R, et al.
Volume & Issue
Volume 19, Issue 8
Pages
1241-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…  
  • Reducing secondary bone fractures can reduce medicare spending
    Reducing 5-20 percent of “secondary” bone fractures in 2015 could have reduced Medicare FFS spending by $310 million to $1.2 billion over a follow-up period that lasted up to 2 to…  
  • 30 drugs are currently in development for osteoporosis.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.